Dialysis filter showdown: could the right membrane tame inflammation?

NCT ID NCT07682701

Ongoing Knowledge-focused Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether the type of filter (membrane) used during hemodialysis changes how immune cells and clotting factors react. Ten adults on long-term dialysis will try three different membranes over one week, with blood samples taken during each session. The goal is to see if any membrane causes less immune activation and clotting, which could lead to safer dialysis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dialyzer membrane (polysulfone, asymmetric triacetate, or polymethyl methacrylate)
What this could lead to: If one membrane type triggers less immune activation and clotting, it could point toward safer dialysis for people with kidney failure.
What could go wrong: This is a very small, short-term study (10 people, 1 week) looking at lab markers, not patient outcomes. Results may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure Thromboinflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE (ESRD) HEMODIALYSIS HEMODIALYSIS TREATMENT THROMBOINFLAMMATION

Contacts and locations

Show contact details

Locations

Universitair Ziekenhuis Brussel

Brussels, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.